Oramed Pharmaceuticals Inc. Logo

Oramed Pharmaceuticals Inc.

Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.

ORMP | TA

Overview

Corporate Details

ISIN(s):
US68403P2039
LEI:
Country:
Israel
Address:
20 Mamilla Avenue, 9414904 Jerusalem
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development of oral drug delivery systems. Established in 2006, the company leverages its proprietary platform technology to transform injectable drugs into oral therapies, aiming to enhance patient comfort, compliance, and safety. Its flagship product is an oral insulin capsule for the treatment of type 2 diabetes, which has undergone extensive clinical development. Oramed's primary focus is on providing non-invasive alternatives to injected medications, particularly for chronic conditions like diabetes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-22 09:42
Post-Annual General Meeting Information
Other Report or Announcement
English 118.7 KB
2025-08-22 09:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-22 09:41
Registration Form
Other Report or Announcement
English 181.3 KB
2025-08-22 09:41
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-17 15:18
Foreign Filer Report
FORM 10-Q- FINANCIAL STATEMENTS AS OF JUNE 30, 2025
English 36.4 KB
2025-08-17 15:16
Major Shareholding Notification
Form 13G
English 93.7 KB
2025-08-17 15:16
Foreign Filer Report
Form 13G
English 36.4 KB
2025-07-23 17:53
Delisting Announcement
Option Agreement for the Repurchase of Warrants
English 316.7 KB
2025-07-23 17:53
Foreign Filer Report
Option Agreement for the Repurchase of Warrants
English 36.4 KB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 1.4 MB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 36.4 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 448.1 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 36.4 KB
2025-07-18 14:50
Annual / Quarterly Financial Statement
Other Report or Announcement
English 359.9 KB
2025-07-18 14:50
Foreign Filer Report
Other Report or Announcement
English 36.4 KB

Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oramed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.